Current Report Filing (8-k)
April 27 2018 - 4:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION
13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report:
April 27, 2018
Commission
File Number
000-54672
_____________________________________________________________
American CryoStem
Corporation
(Exact name of
Registrant as specified in its charter)
____________________________________________________________________________
Nevada
|
7812
|
26-4574088
|
(State
or other
jurisdiction of
incorporation
or organization)
|
(Primary
Standard Industrial
Classification
Code Number)
|
(I.R.S.
Employer Identification
Code
Number)
|
1
Meridian Road, Suite 5
Eatontown,
NJ 07724
|
(Address of principal
executive offices)
|
(732) 747-1007
|
(Registrant’s
telephone number, including area code)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions
(see General Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13-e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
FOWARD LOOKING
STATEMENTS UNDER THE PROVATE SECURITIES LITIGATION REFORM ACT OF 1995
This Current
Report and other reports filed by American CryoStem Corporation ("CRYO" or the "Registrant") from time to
time with the U.S. Securities and Exchange Commission (the “SEC”) contain or may contain forward-looking statements
and information that are based upon beliefs of, and information currently available to, the Registrant’s management as well
as estimates and assumptions made by Registrant’s management. Readers are cautioned not to place undue reliance
on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in
the filings, the words “anticipate,” “believe,” “estimate,” “expect,” “future,”
“intend,” “plan,” or the negative of these terms and similar expressions as they relate to the Registrant
or the Registrant’s management identify forward-looking statements. Such statements reflect the current view
of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including
the risks contained in the “Risk Factors” section of the this Annual Report on Form 10-K., relating to the Registrant’s
industry, the Registrant’s operations and results of operations, and any businesses that the Registrant may acquire. Should
one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results
may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.
ITEM 7.01. Regulation FD Disclosure
Correction of Press Release dated April 5, 2018
The Company today is providing a
correction to the description of Cryoviva Ltd. contained in its press release dated April 5, 2018 titled:
“American CryoStem Enters Into
Agreement to License its Patented Adipose Tissue and Stem Cell Technologies in Thailand”
The “About Cryoviva”
section is updated and corrected to:
About Cryoviva
Cryoviva (Thailand) Ltd. was established
in 2007 with the cooperation of leading companies in the world such as Indorama Ventures (Public) Company Limited, Thailand, Cryoviva
Biotech Pvt., Ltd., (formerly known as Cryobanks International India) and RJ Corp India. Cryoviva is part of a large group
engaged in healthcare comprising of stem cell banks, stem cell expansion facilities, diagnostic labs and centres and a maternal
hospital. The Company has been certified by AABB and the ISO 9001: 2008 Quality Management System. Cryoviva (Thailand)
Co., Ltd. is the only stem cell bank that has been approved by the Board of Investment of Thailand (BOI) and accredited
by AABB in Thailand and awarded Frost & Sullivan’s Thailand Stem Cell Company of the year for three consecutive years
between 2015-2017.
ITEM 9.01. FINANCIAL STATEMENTS
AND EXHIBITS.
Exhibit 99.1 Corrected press release
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AMERICAN CRYOSTEM CORPORATION
|
|
By:
|
/s/ John S. Arnone
|
|
John S. Arnone
|
|
President, CEO and Chairman of the Board
|
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2023 to Jul 2024